Novartis Q3 net income drops 70% to USD 1.2 billion
Bitget2026/10/27 06:01- Novartis' third-quarter 2026 net income fell 70% to USD 1.2 billion due to lower operating income and higher interest expense.
- Net sales rose to USD 14.52 billion, with volume growth partly offset by generic competition.
- A USD 1.9 billion partial impairment affected del-desiran; the drug missed its Phase III primary endpoint in myotonic dystrophy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Trump Media & Technology Group plunges over 24%, hitting a new low since listing.
South Korea’s current account surplus in September exceeded 60 billions USD for the first time, with semiconductor exports becoming the main driver
Driven by booming semiconductor exports, South Korea's current account surplus in September surged to a record high.
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.
AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Crypto prices
More
